Современная фармакотерапия псориатического артрита
https://doi.org/10.14412/1995-4484-2019-75-82
Аннотация
В лекции представлены современные принципы лечения псориатического артрита (ПсА) с учетом гетерогенности проявлений этого заболевания и наличия коморбидных состояний, информация об эффективности и переносимости препаратов, которые применяются в Российской Федерации при ПсА.
Об авторах
Ю. Л. Корсакова
ФГБНУ «Научноисследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
старший научный сотрудник лаборатории диагностики и инновационных методов лечения псориатического артрита, канд. мед. наук;
115522, Москва, Каширское шоссе, 34А
Т. В. Коротаева
ФГБНУ «Научноисследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
заведующая лабораторией диагностики и инновационных методов лечения псориатического артрита, докт. мед. наук;
115522, Москва, Каширское шоссе, 34А
Список литературы
1. Scarpa R, Altomare G, Marchesoni A, et al. Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol. 2010;24:627-30. doi: 10.1111/j.1468-3083.2010.03574.x
2. Smolen J, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017;0:1-15. doi: 10.1136/Ann Rheum Dis-2017-211734
3. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489-98. doi: 10.1016/S0140-6736(15)00347-5
4. Gossec L, Smolen, J, Gaujoux-Viala C, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4-12. doi: 10.1136/annrheumdis-2011-200350
5. Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013;27:1022-5. doi: 10.1111/j.1468-3083.2012.04656.x
6. Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2018. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2018. 464 p. (In Russ.)].
7. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010;28:S132-7.
8. Clegg D, Reda D, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veteran's affairs cooperative study. Arthritis Rheum. 1999;42:2325-9. doi: 10.1002/1529-0131(199911)42:11<2325::AIDANR10>3.0.CO;2-C
9. Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol. 1998;25:1957-61.
10. Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006;212:238-49. doi: 10.1159/000091251
11. Sakellariou G, Sayegh F, Anastasilakis A, et al. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int. 2013;33:2917-20. doi: 10.1007/s00296-012-2534-x
12. Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken). 2013;65:464-70. doi: 10.1002/acr.21848
13. Curtis J, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69:43-7. doi: 10.1136/ard.2008.101378
14. Fraser A, van Kuijk A, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-64. doi: 10.1136/ard.2004.024463
15. Karanikolas G, Koukli E, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol. 2011;38:2466-74. doi: 10.3899/jrheum.110242
16. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-90. doi: 10.1016/j.bcp.2012.01.001
17. Корсакова ЮЛ, Денисов ЛН. Эффективность и безопасность нового препарата для лечения псориаза и псориатического артрита – апремиласта. Научно-практическая ревматология. 2016;54(5):572-7 [Korsakova YuL, Denisov LN. The efficacy and safety of the new drug apremilast for the treatment of psoriasis and psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):572-7 (In Russ.)]. doi: 10.14412/1995-4484-2016-572-577
18. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi: 10.1136/annrheumdis-2013-205056
19. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Long-term (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42:479-88. doi: 10.3899/jrheum.140647
20. Mease PJ, Adebajo AO, Gladman DD. Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial and open-label extension [abstract]. Arthritis Rheum. 2014;66 Suppl 10:1564.
21. Cutolo M, Myerson GR, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724-34. doi: 10.3899/jrheum.151376
22. Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065-73. doi: 10.1136/annrheumdis-2015-207963
23. Wells A, Edwards C, Adebajo AO. Long-term (104-week) safety and efficacy of monotherapy with apremilast in DMARD-naХve patients with psoriatic arthritis: a phase 3, randomized, controlled trial and open-label extension (PALACE 4) [abstract]. Arthritis Rheum. 2014;66 Suppl. 10:L22.
24. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537-50. doi: 10.1056/NEJMoa1615975
25. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377:1525-36. doi: 10.1056/NEJMoa1615977
26. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90. doi: 10.1016/S0140-6736(00)02530-7
27. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72. doi: 10.1002/art.20335
28. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-21.
29. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147. doi: 10.1136/bmj.c147
30. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869-76.
31. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degreeof clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66:498-505. doi: 10.1136/ard.2006.058339
32. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541-8. doi: 10.1136/ard.2011.152223
33. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702-9. doi: 10.1136/ard.2008.092767
34. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying anti-rheumatic drug therapy. J Rheumatol. 2007;34:1040-50.
35. Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a longterm extension of the randomised, placebo-controlled GOREVEAL study. Ann Rheum Dis. 2013;72:1777-85. doi: 10.1136/annrheumdis-2012-202035
36. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73:1689-94. doi: 10.1136/annrheumdis-2013-204902
37. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48-55. doi: 10.1136/annrheumdis-2013-203696
38. Van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73:233-7. doi: 10.1136/annrheumdis-2013-203697
39. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40. doi: 10.1016/S0140-6736(09)60140-9
40. McInnes IB, Kavanaugh A, Gottlieb AB, et al. on behalf of the PSUMMIT I Study Group: Efficacy and safety of Ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial. Lancet. 2013;382:780-9. doi: 10.1016/S0140-6736(13)60594-2
41. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000-6. doi: 10.1136/annrheumdis-2013-204741
42. Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67:1739-49. doi: 10.1002/acr.22645
43. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, doubleblind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990-9. doi: 10.1136/annrheumdis-2013-204655
44. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329-39. doi: 10.1056/NEJMoa1412679
45. Van der Heijde D, Landewe RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheum. 2016;68:1914-21. doi: 10.1002/art.39685
46. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2015;386:1137-46. doi: 10.1016/S0140-6736(15)61134-5
47. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:52. doi: 10.1186/ar2670
48. Marchesoni A, Olivieri I, Salvarani C, et al. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exper Rheumatol. 2017;35:991-1010.
49. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2014;53(8):1377-85. doi: 10.1093/rheumatology/ket409
50. Sieper J, van der Heijde DM, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009;68(6):784-8. doi: 10.1136/ard.2008.101501
51. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978-91. doi: 10.1136/annrheumdis-2016-210770
52. Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a bayesian network meta-analysis. Arch Dermatol. 2012;148:1403-10. doi: 10.1001/2013.jamadermatol.238
53. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326-38. doi: 10.1056/NEJMoa1314258
Рецензия
Для цитирования:
Корсакова Ю.Л., Коротаева Т.В. Современная фармакотерапия псориатического артрита. Научно-практическая ревматология. 2019;57(1):75-82. https://doi.org/10.14412/1995-4484-2019-75-82
For citation:
Korsakova Yu.L., Korotaeva T.V. Modern pharmacotherapy of psoriatic arthritis. Rheumatology Science and Practice. 2019;57(1):75-82. (In Russ.) https://doi.org/10.14412/1995-4484-2019-75-82
Просмотров:
1056
Послать статью по эл. почте 